Clinical Trials Sponsored by Axio Research. LLC

Total 1866 results

Janssen Research & Development, LLC

Completed

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma

United States, Australia, France, Spain, Israel, India, Romania, Korea, Republic of, Singapore, Russian Federation, Poland
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Terminated

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation
Janssen Research & Development, LLC

Completed

Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

Rupture | Abdominal Pain | Appendicitis | Peritonitis | Abdominal Abscess | Infection | Ileus | Intestinal Perforation | Abdomen, Acute | Abscess, Intra-Abdominal

United States, Argentina, Colombia, Chile, Panama, Lithuania, Latvia, Brazil
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

Schizophrenia

Germany, Spain, Bulgaria, Romania, Austria, Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy

Arthritis, Rheumatoid

Poland, Ukraine, Chile, Korea, Republic of, Singapore, Russian Federation, Argentina, Bulgaria, Hungary, Czech Republic
Janssen Research & Development, LLC

Completed

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease

Healthy | Alzheimer Disease

Netherlands, Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device

Healthy

Belgium
Janssen Research & Development, LLC

Completed

An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride

Sexual Dysfunction, Physiological | Ejaculation

Germany, Spain, Portugal, Finland, Sweden, Austria
Janssen Research & Development, LLC

Completed

A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

Healthy

China
Janssen Research & Development, LLC

Completed

Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Diabetes Mellitus, Type 2

United States, Germany, Spain, Mexico, India, Canada, Greece, Thailand, United Kingdom, Finland, France
Janssen Research & Development, LLC

Completed

Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants

Healthy Participants

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

Healthy

United States
Starx Research Center, LLC

Unknown

Ocular Allergy Treatment Practical Impact Trial ((OAT-PIT))

Allergic Conjunctivitis | Rhinoconjunctivitis

United States
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

Healthy Participants

United States
Janssen Research & Development, LLC

Completed

Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene

Healthy Volunteers

Taiwan
Janssen Research & Development, LLC

Completed

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

Healthy Male Volunteer

United States
Janssen Research & Development, LLC

Completed

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Healthy
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Doripenem in Infants Less Than 12 Weeks of Age

Bacterial Infections

United States, United Kingdom, Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men

Healthy Volunteers

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
Biovil Research Group, LLC

Unknown

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

Non Alcoholic Fatty Liver Disease

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

Advanced Stage Solid Tumors

Spain
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
Janssen Research & Development, LLC

Recruiting

A Study of Sterile Saline Infusion in Healthy Volunteers

Healthy Volunteers

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC)

Colitis, Ulcerative

Korea, Republic of, Australia, United States, Czechia, Malaysia, Turkey, Japan, Belgium, Hungary, Canada, Italy, Spain, China, Poland, United Kingdom, Germany, Brazil, France, Argentina, Romania, India
Janssen Research & Development, LLC

Recruiting

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)

Moderate Plaque Psoriasis

United States, Canada
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (MACARONI-23)

Crohn's Disease

Poland, United States, Japan, Norway
Janssen Research & Development, LLC

Recruiting

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE)

Depressive Disorder, Major

United States, Korea, Republic of, Spain, Argentina, Sweden, Germany, Canada, France, Brazil
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Neoplasms

United States, Australia
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple Myeloma | Previously Treated Amyloid Light-chain (AL) Amyloidosis

Belgium, United States, United Kingdom, Spain, France, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Belgium, Korea, Republic of, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Czechia, Netherlands, Poland, Switzerland, Germany
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

Anhedonia | Depressive Disorder, Major

Korea, Republic of, United States, China, Taiwan, Canada, Slovakia, Poland, Argentina, Bulgaria, Czechia, South Africa, United Kingdom, France, Brazil
Janssen Research & Development, LLC

Not yet recruiting

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Acute Leukemias

France
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

Depressive Disorder, Major

United States, Korea, Republic of, Slovakia, Spain, Taiwan, Bulgaria, Poland, Belgium, Argentina, Czechia, Hungary, South Africa, Sweden, Italy, France, Australia, China, Brazil
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, China, France, Denmark, Israel, Poland, Australia
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)

Advanced or Metastatic Colorectal Cancer

United States, Korea, Republic of, Taiwan, Malaysia, Germany, Italy, Spain, Belgium, Canada, Puerto Rico, China
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)

Amyloidosis

Canada, Italy, United States, Greece, China, Netherlands, Spain, France, Germany, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

Crohn's Disease

United States, Denmark, Belgium, Taiwan, Italy, Korea, Republic of, Germany, United Kingdom, Israel, Malaysia, Poland, Japan, New Zealand, Netherlands, China, Canada, France, Spain, Norway, Singapore, Croatia, Brazil, Switzerland, Aus... and more

3

Subscribe